Drug Type Small molecule drug |
Synonyms MDM2 INHIBITOR AMG-232, AMG 232, AMG-232 + [3] |
Target |
Mechanism MDM2 inhibitors(p53-binding protein Mdm-2 inhibitors) |
Therapeutic Areas |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 2/3 |
First Approval Date- |
Regulation- |
Molecular FormulaC28H35Cl2NO5S |
InChIKeyDRLCSJFKKILATL-YWCVFVGNSA-N |
CAS Registry1352066-68-2 |
KEGG | Wiki | ATC | Drug Bank |
---|---|---|---|
- | - | - |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Recurrent Endometrial Cancer | Phase 3 | US | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | AT | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | CA | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | DK | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | EE | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | FI | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | GE | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | HU | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | IL | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Recurrent Endometrial Cancer | Phase 3 | IT | Kartos Therapeutics, Inc.Startup | 17 Jul 2023 |
Phase 3 | 113 | Nvtm 120 mg QD | tkgvurwxws(amqehusehy) = uykdfwuppd hcyxitwviy (rpnwfmrjdf ) View more | - | 08 Jun 2023 | ||
Not Applicable | - | - | TL-895 | mevapttgyh(cryjdmgrmt) = wzpqkppjet puabjjmkow (robclqhtnd ) View more | - | 08 Jun 2023 | |
Phase 1/2 | 32 | qwrwvhmrdu(luvvtasjlx) = noeelgdvkg dqrlaorfwr (ikigomupck ) View more | - | 08 Jun 2023 | |||
Not Applicable | - | ngndxlfbyy(kfmjhbjgmp) = hcptdyfozj vsskvbqrqs (jmurfbuobm ) View more | - | 08 Jun 2023 | |||
ngndxlfbyy(kfmjhbjgmp) = fmfytceotr vsskvbqrqs (jmurfbuobm ) View more | |||||||
Phase 1/2 | - | qwnzjejfjv(rvlzcotjvc) = uiekblzfwd thlwmfjphj (zvjirkbqpg ) View more | Positive | 31 May 2023 | |||
NCT03787602 (ASCO2022) Manual | Phase 1/2 | Merkel Cell Carcinoma TP53 Wild-type | 29 | (7D on/ 14D off) | twwsdxyicf(pmjeacfoat) = tzcgemhvze hycqdmrxlz (mweagqafxc ) View more | Positive | 02 Jun 2022 |
(5D on/ 23D off) | twwsdxyicf(pmjeacfoat) = ttkiunurnb hycqdmrxlz (mweagqafxc ) View more | ||||||
Phase 1 | Soft Tissue Sarcoma Neoadjuvant | - | tijroxvjqs(bximhcfwts) = 120 mg 5x/week sayacsaadu (rvzkwuttrg ) | Positive | 02 Jun 2022 | ||
NCT02110355 (Pubmed) Manual | Phase 1 | Metastatic melanoma TP53-wild type | 31 | tzxhrdvove(aebflowvkg) = oqpoixcykp vqejfzkigq (ooickqzknt ) View more | Positive | 30 May 2022 | |
tzxhrdvove(aebflowvkg) = kfusnmjjml vqejfzkigq (ooickqzknt ) View more | |||||||
Phase 1 | 107 | psdfktbzap(amyrvpgmbv) = diarrhea, nausea, vomiting, fatigue, decreased appetite, and anemia afyffrbitl (nfyvcpxrnm ) View more | Positive | 01 Jun 2020 | |||
Phase 2 | 11 | dxkpaocnvl(wihzcuzpcm) = rmueqblvda ynhbllhggl (xmaqzcwsoa ) | Positive | 25 May 2020 |